Bioactive Suture with Added Innate Defense Functionality for the Reduction of Bacterial Infection and Inflammation
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Bioactive Suture with Added Innate Defense Functionality for the Reduction of Bacterial Infection and Inflammation. / Puthia, Manoj; Petrlova, Jitka; Petruk, Ganna; Butrym, Marta; Samsudin, Firdaus; Andersson, Madelene; Strömdahl, Ann Charlotte; Wasserstrom, Sebastian; Hartman, Erik; Kjellström, Sven; Caselli, Lucrezia; Klementieva, Oxana; Bond, Peter J.; Malmsten, Martin; Raina, Deepak Bushan; Schmidtchen, Artur.
In: Advanced Healthcare Materials, Vol. 12, No. 31, 2300987, 2023.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Bioactive Suture with Added Innate Defense Functionality for the Reduction of Bacterial Infection and Inflammation
AU - Puthia, Manoj
AU - Petrlova, Jitka
AU - Petruk, Ganna
AU - Butrym, Marta
AU - Samsudin, Firdaus
AU - Andersson, Madelene
AU - Strömdahl, Ann Charlotte
AU - Wasserstrom, Sebastian
AU - Hartman, Erik
AU - Kjellström, Sven
AU - Caselli, Lucrezia
AU - Klementieva, Oxana
AU - Bond, Peter J.
AU - Malmsten, Martin
AU - Raina, Deepak Bushan
AU - Schmidtchen, Artur
N1 - Publisher Copyright: © 2023 The Authors. Advanced Healthcare Materials published by Wiley-VCH GmbH.
PY - 2023
Y1 - 2023
N2 - Surgical site infections (SSI) are a clinical and economic burden. Suture-associated SSI may develop when bacteria colonize the suture surface and form biofilms that are resistant to antibiotics. Thrombin-derived C-terminal peptide (TCP)-25 is a host defense peptide with a unique dual mode of action that can target both bacteria and the excessive inflammation induced by bacterial products. The peptide demonstrates therapeutic potential in preclinical in vivo wound infection models. In this study, the authors set out to explore whether TCP-25 can provide a new bioactive innate immune feature to hydrophilic polyglactin sutures (Vicryl). Using a combination of biochemical, biophysical, antibacterial, biofilm, and anti-inflammatory assays in vitro, in silico molecular modeling studies, along with experimental infection and inflammation models in mice, a proof-of-concept that TCP-25 can provide Vicryl sutures with a previously undisclosed host defense capacity, that enables targeting of bacteria, biofilms, and the accompanying inflammatory response, is shown.
AB - Surgical site infections (SSI) are a clinical and economic burden. Suture-associated SSI may develop when bacteria colonize the suture surface and form biofilms that are resistant to antibiotics. Thrombin-derived C-terminal peptide (TCP)-25 is a host defense peptide with a unique dual mode of action that can target both bacteria and the excessive inflammation induced by bacterial products. The peptide demonstrates therapeutic potential in preclinical in vivo wound infection models. In this study, the authors set out to explore whether TCP-25 can provide a new bioactive innate immune feature to hydrophilic polyglactin sutures (Vicryl). Using a combination of biochemical, biophysical, antibacterial, biofilm, and anti-inflammatory assays in vitro, in silico molecular modeling studies, along with experimental infection and inflammation models in mice, a proof-of-concept that TCP-25 can provide Vicryl sutures with a previously undisclosed host defense capacity, that enables targeting of bacteria, biofilms, and the accompanying inflammatory response, is shown.
KW - host defense peptides
KW - polyglactin
KW - surgical site infections
KW - suture
KW - TCP-25
U2 - 10.1002/adhm.202300987
DO - 10.1002/adhm.202300987
M3 - Journal article
C2 - 37689972
AN - SCOPUS:85171534958
VL - 12
JO - Advanced healthcare materials
JF - Advanced healthcare materials
SN - 2192-2640
IS - 31
M1 - 2300987
ER -
ID: 370470826